ProCE Banner Activity

(Neo) Adjuvant Therapy in HER2-Negative Early Breast Cancer Treatment Selection Tool


Learn how 5 experts incorporate the latest evidence on (neo) adjuvant therapy into the management of HER2-negative breast cancer using this Interactive Decision Support Tool.

Released: September 06, 2022

Expiration: September 05, 2023

No longer available for credit.
Begin Activity



Denise A. Yardley

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Jame Abraham

Jame Abraham, MD, FACP

Department of Hematology and Medical Oncology
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Cleveland, Ohio

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Director, Glenn Family Breast Center
Professor of Medicine
Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Tiffany A. Traina

Tiffany A. Traina, MD

Assistant Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Department of Medicine
Weill Medical College of Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from



Merck Sharp & Dohme Corp.


Smart Patients

ProCE Banner

Additional Information

Program Medium

This program has been made available online.